Genprex Inc.

06/09/2025 | Press release | Distributed by Public on 06/09/2025 05:00

Failure to Satisfy Listing Rule (Form 8-K)

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On June 6, 2025, Genprex, Inc. (the "Company") received a letter (the "June 2025 Compliance Letter") from the Listing Qualifications Department (the "Nasdaq Staff") of The Nasdaq Stock Market ("Nasdaq") providing written confirmation that the Company has regained compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement"). The June 2025 Compliance Letter was pursuant to a previous letter received on November 19, 2024 (the "November 2024 Notice") from the Nasdaq Staff indicating, as previously reported, that the Company was not then in compliance with the Stockholders' Equity Requirement because the Company's stockholders' equity as reported in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, was below the required minimum of $2.5 million, and because, as of the date of the November 2024 Notice, the Company did not meet either of the alternative compliance standards, relating to market value of listed securities of at least $35 million or net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years, as set forth in Listing Rules 5550(b)(1), or 5550(b)(2), or 5550(b)(3), respectively (the "Rules"). The June 2025 Compliance Letter stated that based on the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Securities and Exchange Commission on May 12, 2025, the Nasdaq Staff has determined that the Company complies with the Rules and the matter is now closed.
As previously reported, on February 7, 2025, the Company received a letter (the "February 2025 Notice") from the Nasdaq Staff notifying the Company that, based upon the closing bid price of the Company's common stock for the prior 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). As previously reported, in accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until August 6, 2025, to regain compliance with the Minimum Bid Price Requirement. The Company intends to continue to monitor the closing bid price of its common stock and assess potential actions to regain compliance with the Minimum Bid Price Requirement and may, if appropriate, consider and effectuate available options, including implementation of a reverse stock split of the Company's common stock. If Nasdaq were to determine to delist the Company's common stock for failure to satisfy the Minimum Bid Price Requirement, the Company would have the right to appeal to a Nasdaq hearings panel, but there can be no assurance that any such appeal would be successful.
Genprex Inc. published this content on June 09, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 09, 2025 at 11:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io